Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia.
Corresponding author: Lisa G. Hofler, MD, MPH, MBA, Department of Obstetrics and Gynecology, University of New Mexico, 1 University of New Mexico, MSC10 5580, Albuquerque, NM 87131; email: [email protected].
Supported by a grant from the Society of Family Planning Research Fund.
Financial Disclosure Dr. Cwiak has received research funding for an intrauterine device clinical trial from Medicines 360 and has served as a faculty trainer on Nexplanon for Merck. Dr. Kottke has served as a faculty trainer on Nexplanon for Merck, has served as a consultant for CSL Behring, and has served on the advisory board for Evofem, Inc. The other authors did not report any potential conflicts of interest.
Presented at the 2016 North American Forum on Family Planning, November 4–7, 2016, Denver, Colorado.
The authors thank Sandra Naoom, PhD, MSPH, from the National Implementation Research Network, University of North Carolina, Chapel Hill, for her assistance with topic development for this study.
The Society of Family Planning Research Fund had no involvement in the study design; data collection, interpretation, or analysis; writing of the report; or the decision to submit for publication.
Each author has indicated that he or she has met the journal's requirements for authorship.